ANDA 205343, held by Chartwell Rx. Flurandrenolide.
As of Nov 16, 2026, ANDA 205343 (Flurandrenolide), held by Chartwell Rx, was first approved by FDA on Dec 22, 2016, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 22, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Flurandrenolide0.05% ยท lotion;topical | Flurandrenolide | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters